natgillin/translations-raw huggingface dataset:
Tonsillitis/pharyngitis caused by Group A beta streptococci, as an alternative when beta lactam antibiotics are not appropriate.
tonzilitis/faringitis, ki ga povzročajo beta- streptokoki skupine A, kot alternativno zdravilo, kadar betalaktamski antibiotiki niso primerni.
Tonsillitis/pharyngitis caused by Streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of macrolide resistant S. pyogenes, when mediated by ermTR or mefA (see sections 4.4 and 5.1).
Tonzilitisa/faringitisa, ki ga povzroča Streptococcus pyogenes, kot alternativa, kadar betalaktamski antibiotiki niso primerni v državah/regijah s signifikantno prevalenco proti makrolidom odpornega S. pyogenes, če je odpornost posledica ermTR ali mefA (glejte poglavji 4.4 in 5.1).
Tonsillitis/pharyngitis caused by Streptococcus pyogenes: 800 mg once a day for 5 days.
Tonzilitis/faringitis, ki ga povzroča Streptococcus pyogenes: 800 mg enkrat na dan 5 dni.
Tonsillitis†
tonzilitis
Too activate the “initiation/titration” menu you need to first select
Za aktiviranje menija "začetek/titriranje" morate najprej izbrati
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
Prepogosta in ponavljajoča se uporaba antihelmintikov istega razreda, v predolgem časovnem obdobju.
Too high blood sugar (hyperglycaemia)
Previsok krvni sladkor (hiperglikemija)
Too little sugar in the blood (hypoglycaemia),
pomanjkanje sladkorja v krvi (hipoglikemija),
Too low blood sugar (hypoglycaemia)
Prenizek krvni sladkor (hipoglikemija)
Too low blood sugar may happen if you:
Prenizek krvni sladkor se vam lahko pojavi, če:
Too much fluid collecting in the tissues due to irregular lymph function
prekomerno zastajanje tekočine v tkivih zaradi motenega odtoka limfe,
Too much growth hormone can cause greater than normal growth of ears, nose, lips, tongue and cheekbone (acromegaly), high blood sugar (hyperglycaemia) and presence of sugar in the urine (glucosuria).
Preveč rastnega hormona lahko povzroči povečano rast ušes, nosu, jezika in ličnic (akromegalijo), povišano raven sladkorja v krvi (hiperglikemijo) in prisotnost sladkorja v urinu (glukozurijo).
too much iron in your body bowel inflammation
preveč železa v telesu, črevesno vnetje.
Too much of inhaled nitric oxide may influence the oxygen carrying capacity of the blood.
Vdihavanje dušikovega oksida lahko vpliva na sposobnost krvi za prenašanje kisika.
Too much saliva
čezmerno slinjenje
Too much saliva and dehydration
Čezmerno slinjenje in dehidracija
Too much saliva and dehydration
čezmerno slinjenje in dehidracija,
too much sugar in the blood,
visok krvni sladkor,
Too rapid correction of hyponatraemia (increase ≥ 12 mmol/l/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma or death.
Prehiter popravek hiponatriemije (povečanje ≥ 12 mmol/l/24 ur) lahko povzroči osmotsko demielinizacijo, ki povzroči disartrijo, mutizem, disfagijo, letargijo, afektivne spremembe, spastično kvadriparezo, epileptične napade, komo ali smrt.
Tooth discolouration
Bolečine v trebuhu Flatulenca Sprememba barve zob
Tooth extraction
ekstrakcija zoba
Tooth extraction, cholecystectomy
ekstrakcija zoba, holecistektomija
Tooth infection
okužba zob
Tooth infection,
zobna okužba,
Tooth infection, genital herpes, onychomycosis
zobna okužba, genitalni herpes, onihomikoza
tooth infection, nail fungal infection, infection in the muscles, blood stream infection, collection of pus under the skin, kidney infection
okužba zob, glivična okužba nohtov, okužba mišic, okužba krvi, podkožno gnojno vnetje, okužba ledvic,
tooth infection, nail fungal infection, infection in the muscles, blood stream infection, collection of pus under the skin, kidney infection, inflammation of uterus, fallopian tubes and/or ovaries
okužba zob, glivična okužba nohtov, okužba mišic, okužba krvi, podkožno gnojno vnetje, okužba ledvic, vnetje maternice, jajcevodov in/ali jajčnikov,
Toothache
zobobol
Toothache
zobobol,
toothache changes in the colour of the skin.
zobobol spremembe barve kože.
top blood clots forming in your blood in the following situations:
preprečevanje nastanka krvnih strdkov v krvi v naslednjih primerih:
Top Injection button
Vrh Gumb za injiciranje
Top of plunger
Vrh bata
top taking this medicine and tell your doctor straight away.
prenehajte jemati to zdravilo in takoj obvestite svojega zdravnika.
top the inhalation session talk to your doctor
prekinite z inhaliranjem, se posvetujte z zdravnikom.
Topical application of diesters results in high therapeutic index: high local activity with reduced systemic secondary effects.
Rezultat lokalne uporabe diestrov je visoki terapevtski indeks: visoko lokalno delovanje z reduciranimi sekundarnimi sistemskimi učinki.
Topical in vivo application of imiquimod cream on mouse skin resulted in increased concentrations of IFN and tumour necrosis factor (TNF) compared with skin of untreated mice.
V in vivo pogojih je lokalno nanašanje imikvimod kreme na kožo miši, v primerjavi s kožo nezdravljenih miši, povzročilo zvišanje koncentracij IFN in tumorje nekrotizirajočega faktorja (TNF).
Topical ocular administration of travoprost to monkeys at concentrations of up to 0.012% to the right eye, twice daily for one year resulted in no systemic toxicity.
Topikalna okularna uporaba travoprosta na desnem očesu pri opicah, v koncentracijah do 0,012% dvakrat na dan, v času enega leta, ni povzročila nikakršnih sistemskih toksičnih učinkov.
Topical ocular administration of travoprost to monkeys at concentrations of up to 0.012% to the right eye, twice daily for one year resulted in no systemic toxicity.
Topikalna okularna uporaba travoprosta pri opicah v koncentracijah do 0,012% na desnem očesu dvakrat na dan v času enega leta ni povzročila nikakršne sistemske toksičnosti.
Topically applied medicinal products (such as silver sulfadiazine or povidone-iodine) at the wound site must be removed and the wound cleansed prior to NexoBrid application.
Pred nanosom zdravila NexoBrid je treba topikalno nanesena zdravila (kot sta srebrov sulfadiazin ali povidon-jod) odstraniti in rano očistiti.
Topically applied medicinal products (such as silver sulfadiazine or povidone-iodine) at the wound site must be removed and the wound must be cleansed prior to NexoBrid application.
Pred nanosom zdravila NexoBrid je treba topikalno nanesena zdravila (kot sta srebrov sulfadiazin ali povidon-jod) odstraniti in rano očistiti.
Topically applied medicinal products (such as silver sulfadiazine or povidone-iodine) at the wound site must be removed and the wound must be cleansed prior to NexoBrid application.
Pred nanosom zdravila NexoBrid je treba topikalno nanesena zdravila (kot sta srebrov sulfadiazin ali povidon-jod) z rane odstraniti in rano očistiti.
topiramate used to treat epilepsy
topiramat, ki se uporablja za zdravljenje epilepsije;
Topotecan
topotekan
topotecan (used to treat cancer)
topotekan (za zdravljenje raka)
Topotecan Actavis
Topotekan Actavis
Topotecan Actavis 1 mg powder for concentrate for solution for infusion
Topotekan Actavis 1 mg prašek za koncentrat za raztopino za infundiranje
Topotecan Actavis 1 mg powder for concentrate for solution for infusion topotecan
Topotekan Actavis 1 mg prašek za koncentrat za raztopino za infundiranje topotekan
Topotecan Actavis 1 mg with 1.1 ml water for injections (as it contains 10 % overage of fill)
Topotekan Actavis 1 mg z 1,1 ml vode za injekcije (ker vsebuje 10% prepolnjenja)
Topotecan Actavis 4 mg powder for concentrate for solution for infusion
Topotekan Actavis 4 mg prašek za koncentrat za raztopino za infundiranje
Topotecan Actavis 4 mg powder for concentrate for solution for infusion topotecan
Topotekan Actavis 4 mg prašek za koncentrat za raztopino za infundiranje topotekan
Topotecan Actavis 4 mg with 4 ml water for injections
Topotekan Actavis 4 mg s 4 ml vode za injekcije
Topotecan Actavis can make you feel tired or weak.
Zdravilo Topotekan Actavis lahko povzroči utrujenost in šibkost.
Topotecan Actavis contains sodium
Zdravilo Topotekan Actavis vsebuje natrij
Topotecan Actavis INSTRUCTIONS ON USE
Topotekan Actavis NAVODILA ZA UPORABO
Topotecan Actavis is a ‘generic medicine’.
Zdravilo Topotecan Actavis je „generično zdravilo“.
Topotecan Actavis is not recommended in case of severe kidney impairment; if you have liver problems.
Zdravila Topotekan Actavis ni priporočljivo uporabljati pri bolnikih s hudo okvaro ledvic. če imate težave z jetri.
Topotecan Actavis is not recommended in case of severe liver impairment; if you suffer from lung inflammation with signs such as cough, fever and difficulties in breathing, see also section 4 “Possible side effects”.
Zdravila Topotekan Actavis ni priporočljivo uporabljati pri bolnikih s hudo okvaro jeter. če imate vnetje pljuč z znaki, kot so kašelj, zvišana telesna temperatura in težave z dihanjem; glejte tudi poglavje 4, "Možni neželeni učinki".
Topotecan Actavis is supplied in type I colourless glass vials with grey bromobutylic stopper and aluminium seals with plastic flip-off caps.
Zdravilo Topotekan Actavis je na voljo v vialah iz brezbarvnega stekla tipa I s sivim brombutilnim zamaškom in aluminijsko zaporo s plastično snemno zaporko.
Topotecan Actavis is used to treat:
Zdravilo Topotekan Actavis uporabljamo za zdravljenje:
Topotecan Actavis may reduce your ability to fight infections.
Zdravilo Topotekan Actavis lahko zmanjša vašo sposobnost za premagovanje okužb.
Topotecan Actavis topotecan
Topotecan Actavis topotekan
Topotecan also had a high volume of distribution, about 132 1, (SD 57) and a relatively short half-life of 2-3 hours.
Topotekan ima tudi velik volumen porazdelitve, približno 132 l (SD 57), in sorazmerno kratko razpolovno dobo, 2-3 ure.
Topotecan also had a high volume of distribution, about 132 l, (SD 57) and a relatively short half-life of 2-3 hours.
Topotekan ima tudi velik porazdelitveni volumen, približno 132 l (SD 57), in sorazmerno kratko razpolovno dobo, 2 do 3 ure.
Topotecan can make you feel tired.
Zaradi prejemanja topotekana boste lahko postali utrujeni.
Topotecan Eagle 15 mg/5 ml concentrate for solution for infusion
Topotekan Eagle 15 mg/5 ml koncentrat za raztopino za infundiranje
Topotecan Eagle 3 mg/1 ml concentrate for solution for infusion
Topotekan Eagle 3 mg/1 ml koncentrat za raztopino za infundiranje
Topotecan Eagle 3 mg/1 ml concentrate for solution for infusion topotecan
Topotekan Eagle 3 mg/1 ml koncentrat za raztopino za infundiranje topotekan
Topotecan Eagle can make you feel tired or weak.
Zdravilo Topotekan Eagle lahko povzroči utrujenost ali šibkost.
Topotecan Eagle concentrate is clear yellow to orange in colour and contains 3 mg/ml of topotecan, which is a higher concentration than found in other topotecan products for intravenous infusion.
Zdravilo Topotekan Eagle je bister, rumen do oranžen koncentrat, ki vsebuje 3 mg/ml topotekana, kar je večja koncentracija kot pri drugih zdravilih s topotekanom za intravensko infundiranje.
Topotecan Eagle is a clear yellow to orange liquid in a colourless glass vial with a butyl rubber stopper, aluminium seal and blue snap-cap and with yellow vial ring collar.
Zdravilo Topotekan Eagle je bistra, rumena do oranžna tekočina v viali iz prozornega stekla, ki je opremljena z zamaškom iz butilne gume, aluminijasto zaporko z modrim pokrovom in rumenim obročkom.
Topotecan Eagle is a clear yellow to orange liquid in a colourless glass vial with a butyl rubber stopper, aluminium seal and yellow snap-cap and with yellow vial ring collar.
Zdravilo Topotekan Eagle je bistra, rumena do oranžna tekočina v viali iz prozornega stekla, ki je opremljena z zamaškom iz butilne gume, aluminijasto zaporko z modrim pokrovom in rumenim obročkom.
Topotecan Eagle is a ‘hybrid generic medicine’.
Zdravilo Topotecan Eagle je „generično zdravilo“.
Topotecan Eagle is normally given by a doctor or nurse:
Zdravilo Topotekan Eagle običajno daje zdravnik ali medicinska sestra:
Topotecan Eagle is supplied in cartons containing 1 vial.
Zdravilo Topotekan Eagle je na voljo v škatlah z 1 vialo.
Topotecan Eagle should not be used during pregnancy, unless clearly necessary.
Zdravila Topotekan Eagle ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
Topotecan Eagle topotecan
Topotecan Eagle topotekan
Topotecan Hospira
Topotekan Hospira
Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion topotecan
Topotecan Hospira 1 mg/ml koncentrat za raztopino za infundiranje topotekan
Topotecan Hospira is a clear, yellow or yellow-green concentrate for solution for infusion supplied in clear glass vials, each containing 4 ml concentrate.
Zdravilo Topotecan Hospira je bister rumen ali rumenkasto zelen koncentrat za raztopino za infundiranje, ki je pakiran v prozorne steklene viale s po 4 ml koncentrata.
Topotecan Hospira is a concentrated solution which will be diluted before use.
Zdravilo Topotecan Hospira je koncentrirana raztopina, ki jo bodo pred uporabo razredčili.
Topotecan Hospira is a ‘hybrid medicine’.
Topotecan Hospira je „hibridno zdravilo“.
Topotecan Hospira is an anti-cancer medicine, which will be given to you through a drip, as an infusion into a vein.
Topotecan Hospira je zdravilo proti raku, ki ga boste prejeli po kapalni infuziji v veno.
Topotecan Hospira with food and drink
Zdravilo Topotecan Hospira skupaj s hrano in pijačo
Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease.
Topotekan v kombinaciji s cisplatinom je indiciran pri bolnicah s ponovitvijo carcinoma materničnega vratu po zdravljenju z obsevanjem in bolnicah s stadijem IVB karcinoma materničnega vratu.
Topotecan inhibits topoisomerase-I by stabilising the covalent complex of enzyme and strand-cleaved DNA which is an intermediate of the catalytic mechanism.
Topotekan zavira topoizomerazo I tako, da stabilizira kovalentni kompleks tega encima in ene verige DNA, ki je vmesni produkt katalitičnega mehanizma.
Topotecan is a substrate for both ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
Topotekan je substrat ABCB1 (glikoprotein P) in ABCG2 (BCRP).
Topotecan is contraindicated in patients who
Topotekan je kontraindiciran pri bolnikih oziroma bolnicah:
Topotecan is contraindicated in patients who
Topotekan je kontraindiciran pri:
Topotecan is not recommended to be used in these patients.
Uporaba topotekana pri teh bolnikih ni priporočljiva.
Topotecan may reduce the number of white blood cells in your body and make you more likely to get an infection.
Topotekan lahko zmanjša število belih krvničk v telesu in naredi bolnika bolj dovzetnega za okužbe.
Topotecan monotherapy and topotecan in combination with cisplatin are commonly associated with clinically relevant thrombocytopenia.
Uporabo samega topotekana in topotekana v kombinaciji s cisplatinom pogosto spremlja klinično pomembna trombocitopenija.
Topotecan must be further diluted before use (see section 6.6).
Pred uporabo je treba topotekan dodatno razredčiti (glejte poglavje 6.6).
Topotecan must be further diluted before use (see section 6.6).
Pred uporabo je treba topotekan rekonstituirati in nato še nadalje razredčiti (glejte poglavje 6.6).
Topotecan plus cisplatin had a statistically significant benefit in overall survival relative to cisplatin monotherapy after adjusting for interim analyses (Log-rank p =0.033).
Pri vmesni analizi je imela kombinacija topotekana in cisplatina statistično pomembno korist na skupno preživetje v primerjavi z zdravljenjem s samim cisplatinom (log-rank p = 0,033).
Topotecan should not be re-administered unless the neutrophil count is ≥ 1 x 109/l, the platelet count is ≥ 100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).
Pred naslednjo uporabo topotekana mora biti število nevtrofilcev ≥ 1 x 109/l, število trombocitov ≥ 100 x 109/l, vrednost hemoglobina pa ≥ 9 g/dl (po transfuziji, če je le-ta potrebna).
Topotecan should not be re-administered unless the neutrophil count is  1 x 109/l, the platelet count is
Pred naslednjo uporabo topotekana mora biti število nevtrofilcev  1 x 109/l, število trombocitov
Topotecan should not be re-administered unless the neutrophil count is  1 x 109/l, the platelet count is
Topotekana ne smete ponovno uporabiti, dokler ni število nevtrofilcev ≥ 1 x 109/l, število trombocitov
Topotecan should not be re-administered unless the neutrophil count is  1 x 109/l, the platelet count is
Topotekana ne smete ponovno uporabiti, dokler ni število nevtrofilcev  1 x 109/l, število trombocitov
Topotecan Teva
Topotekan Teva
Topotecan Teva 1 mg/1 ml concentrate for solution for infusion
Topotekan Teva 1 mg/1 ml koncentrat za raztopino za infundiranje
Topotecan Teva 4 mg/4 ml concentrate for solution for infusion
Topotekan Teva 4 mg/4 ml koncentrat za raztopino za infundiranje
Topotecan Teva is a ‘generic medicine’.
Topotecan Teva je „generično zdravilo“.
Topotecan Teva is available in cartons containing 1 vial and 5 vials.
Topotekan Teva je na voljo v škatlah z 1 vialo in 5 vialami.
Topotecan Teva is contraindicated in patients who
Zdravilo Topotekan Teva je kontraindicirano pri
Topotecan Teva is supplied in cartons containing 1 vial or 5 vials.
Topotekan Teva je na voljo v škatlah z 1 vialo ali 5 vialami.
Topotecan Teva is used to treat:
Zdravilo Topotekan Teva se uporablja pri zdravljenju:
Topotecan Teva topotecan
Topotecan Teva topotekan
Topotecan was also shown to cause embryo-foetal lethality when given to rats and rabbits.
Pri podganah in kuncih je topotekan povzročil smrt zarodkov oz. plodov.
topotecan, a medicine used to treat certain types of cancer.
topotekan, zdravilo proti določenim vrstam raka,
torage precautions for reconstituted solution
Pogoje shranjevanja rekonstituirane raztopine.
torasemide (used to increase urine flow),
torazemid (uporablja se za povečanje izločanja urina),
Torasemide should be used with caution in cases of diabetes mellitus, and in dogs with previously prescribed high doses of an alternative loop diuretic.
Torasemid je potrebno uporabljati previdno v primerih sladkorne bolezni in pri psih s predhodno predpisanimi visokimi odmerki alternativnih diuretikov Henleyjeve zanke.
Torasemide treatment should not be initiated in dogs already clinically stable on an alternative diuretic for treatment of the signs of congestive heart failure, except where this has been justified taking into account the risk of de-stabilising the clinical condition and of adverse reactions as indicated in section 4.6.
Zdravljenje s torasemidom se ne sme začeti pri psih, ki so že klinično stabilni na alternativnem diuretiku za zdravljenje znakov kongestivnega srčnega popuščanja, razen če je to upravičeno ob upoštevanju tveganja za destabilizacijo kliničnega stanja in neželenih učinkov, kot je navedeno v poglavju 4.6.
Torasemide treatment should not be initiated in dogs already clinically stable on an alternative diuretic for treatment of the signs of congestive heart failure, except where this has been justified taking into account the risk of de-stabilising the clinical condition and of adverse reactions as indicated in section 6.
Zdravljenje s torasemidom se ne sme začeti pri psih, ki so že klinično stabilni na alternativnem diuretiku za zdravljenje znakov kongestivnega srčnega popuščanja, razen če je to upravičeno ob upoštevanju tveganja za destabilizacijo kliničnega stanja in neželenih učinkov, kot je navedeno v poglavju 6.
TORCH was a 3-year study to assess the effect of treatment with salmeterol/fluticasone propionate inhalation powder 50/500 micrograms twice daily, salmeterol inhalation powder 50 micrograms twice daily, fluticasone propionate (FP) inhalation powder 500 micrograms twice daily or placebo on all-cause mortality in patients with COPD.
TORCH je bila tri leta trajajoča študija, katere cilj je bil pri bolnikih s KOPB oceniti učinek zdravljenja s salmeterolom/flutikazonpropionatom 50/500 mikrogramov dvakrat na dan, s salmeterolom 50 mikrogramov dvakrat na dan, s flutikazonpropionatom (FP) 500 mikrogramov dvakrat na dan ali s placebom na umrljivost zaradi vseh vzrokov pri bolnikih s KOPB.
toremifene (used to treat breast cancer). fusidic acid (an antibiotic).
toremifen (ki ga uporabljamo za zdravljenje raka dojk), fusidno kislino (antibiotik).
Toremifene binds specifically to estrogen receptors, competitively with oestradiol, and inhibits estrogen- induced stimulation of DNA synthesis and cell replication.
Toremifen se specifično veže na estrogenske receptorje, kompetitivno z estradiolom, in zavira z estrogeni inducirano stimulacijo sinteze DNA in celično replikacijo.
Toremifene has no influence on the ability to drive and use machines.
Toremifen nima vpliva na sposobnost vožnje in upravljanja s stroji.
Toremifene is recommended for postmenopausal patients.
Toremifen priporočamo za bolnice po menopavzi.
Toremifene should be used cautiously in patients with liver impairment (see section 5.2).
Toremifen je treba uporabljati previdno pri bolnicah z jetrno okvaro (oglejte poglavje 5.2).
Torisel 30 mg concentrate and diluent for solution for infusion
Torisel 30 mg koncentrat in vehikel za raztopino za infundiranje
Torisel 30 mg concentrate and diluent for solution for infusion temsirolimus
Torisel 30 mg koncentrat in vehikel za raztopino za infundiranje temsirolimus
Torisel 30 mg concentrate and diluents for solution for infusion
Torisel 30 mg koncentrat in vehikel za raztopino za infundiranje temsirolimus
Torisel 30 mg concentrate must be diluted with 1.8 ml of withdrawn diluent before administration in sodium chloride 9 mg/ml (0.9%) solution for injection.
Preden zdravilo Torisel 30 mg koncentrat uporabite v raztopini natrijevega klorida 9 mg/ml (0,9 %), ga morate razredčiti z 1,8 ml vehikla, odvzetega iz priložene viale.
Torisel 30 mg concentrate must be diluted with the supplied diluent before administration in sodium chloride infusion.
Preden zdravilo Torisel 30 mg koncentrat uporabimo v infuziji natrijevega klorida, ga moramo razredčiti z vehiklom iz priložene viale.
Torisel 30 mg concentrate must first be diluted with 1.8 ml of withdrawn diluent to achieve a concentration of 10 mg/ml before administration in sodium chloride 9 mg/ml (0.9%) solution for injection (see dilution instructions at the end of the package leaflet).
Pred dodajanjem v raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje je treba zdravilo Torisel 30 mg koncentrat najprej razredčiti z 1,8 ml vehikla, odvzetega iz priložene viale, da doseže koncentracijo 10 mg/ml (glejte navodila za redčenje na koncu navodila za uporabo).
Torisel can decrease the number of blood cells that help in clotting and resisting infection which may increase the risk of bleeding/bruising and infection (see section “Possible side effects").
Zdravilo Torisel lahko zmanjša število krvnih celic, ki sodelujejo pri strjevanju krvi ter premagovanju okužb, kar lahko poveča tveganje za krvavitve/podplutbe in okužbe (glejte poglavje “Možni neželeni učinki”).
Torisel concentrate and diluent should be inspected visually for particulate matter and discolouration prior to administration.
Koncentrat in vehikel zdravila Torisel je treba pred dajanjem pregledati s prostim očesom glede prisotnosti delcev in obarvanja.
Torisel has no known influence on the ability to drive and use machines based on the evidence available.
Zdravilo Torisel nima vpliva na sposobnost vožnje in upravljanja s stroji, glede na razpoložljive podatke.
Torisel has no known influence on the ability to drive and use machines.
Zdravilo Torisel nima vpliva na sposobnost vožnje in upravljanja s stroji.
Torisel has not been studied in patients undergoing haemodialysis.
Pri bolnikih na hemodializi zdravila Torisel niso proučevali.
Torisel has not been studied in pregnant women, and it must not be used during pregnancy.
Zdravila Torisel pri nosečnicah niso raziskovali in ga v nosečnosti ne smete uporabljati.
Torisel infusion should be interrupted in all patients with severe infusion reactions and appropriate medical therapy administered.
Pri vseh bolnikih s hudimi reakcijami na infuzijo je treba infuzijo zdravila Torisel prekiniti in poskrbeti za ustrezno medicinsko zdravljenje.